Novavax's COVID-19 Vaccine Rollout Off To Sluggish Start Wit

Since its emergency authorization final month, simply 7,300 doses of Novavax’s COVID-19 vaccine have been administered to People throughout the nation, newly up to date information from the Facilities for Illness Management and Prevention (CDC) exhibits.

In accordance with John Brownstein, Ph.D., an epidemiologist at Boston Youngsters’s Hospital and an ABC Information contributor, the sluggish onset could also be due, partly, to the truth that vaccines weren’t supplied instantly after authorization, and Thus, there could also be some reporting delay.

Complete Novavax doses symbolize solely a fraction of the pictures administered into the arms every day, though the overall variety of vaccines administered has decreased in latest months.

A well being employee prepares a dose of the COVID-19 vaccine from Novavax in Utrecht, the Netherlands, on March 15, 2022. In contrast to mRNA vaccines, it doesn’t must be saved in ultra-low temperatures, giving it a logistical benefit in hard-to-find situations. Entry areas.

Jeroen Jumlett / ANP through AFP / Getty Photos

As well as, the vaccine will not be broadly out there, with solely 385 websites initially providing the Novavax vaccine out of greater than 53,000 areas with COVID-19 vaccines, Brownstein stated. Nevertheless, in latest occasions, that quantity has risen to 986 websites, which Brownstein urged might assist speed up.

“Low entry, restricted publicity and the sluggish tempo of the vaccination marketing campaign imply that Novavax has not been of a excessive precedence to the remainder of People,” Brownstein stated. “As provide will increase, we might even see elevated entry however that is unlikely to trigger an actual dent.”

In July, the Biden administration secured 3.2 million doses of Novavax’s COVID-19 vaccine in hopes that some unvaccinated People would get the shot.

Photo: A healthcare worker administers a dose of Novavax COVID-19 vaccine at a pharmacy on August 1, 2022 in Schwanksville, Pa.

A healthcare employee administers a dose of Novavax COVID-19 vaccine at a pharmacy in Schwanksville, Pa., August, 2022. Novavax’s protein-based COVID-19 vaccine obtained long-standing US emergency-use authorization in July.

Bloomberg through Getty Photos

Many well being consultants expressed their hope that some people, who’re nonetheless hesitant to vaccinate, could be extra inclined to obtain the Novavax vaccine, as it’s based mostly on a extra conventional protein-based know-how that already has is getting used. flu vaccine and different pictures, whereas Pfizer and the Moderna Vaccine Platform tapped a brand new genetic know-how — together with messenger RNA — to supply their vaccines.

“A extra conventional supply route ought to be seen as an incentive to persuade individuals who have not rolled up their sleeves but,” Brownstein defined.

Nevertheless, early indicators counsel that authority has but to maneuver the needle with essentially the most hesitant People.

Nonetheless, well being consultants beforehand informed ABC Information that regardless of how widespread using the Novavax vaccine is, it’ll nonetheless save lives.

Nationally, there are nonetheless greater than 26 million American adults who stay utterly uninsured.

There was no vital improve within the variety of individuals receiving the primary COVID-19 dose since November 2021. Since then, the common quantity has dropped to about 50,000 first pictures, administered every day in all eligible age teams.

Apply Here




Leave a Reply